BBOTNasdaqPharmaceutical PreparationsFiscal year ends December 31
BridgeBio Oncology Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$2.85+0.03 (+1.06%)
Close on Oct 19, 2026
- Market cap
- $228.15M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$8.30 (−74.44%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $228.15M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.71
- Dividend yield
- –
- Free cash flow yield
- -66.43%
Fundamentals
- Net income
- -$182.11M
- EPS, diluted
- -$4.30
- Free cash flow
- -$151.56M
- Book value per share
- $4.04
- Diluted shares
- 80M
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Operating income
-$198.96M
Net income
-$182.11M
EPS, diluted
–
Free cash flow
-$151.56M
Reported periodTrailing twelve months